NEW YORK, June 6 (Reuters) - Drugmaker Eli Lilly presented trial results to medical professionals on Saturday showing ‌its next-generation obesity drug retatrutide curbed sleep apnea ‌severity in addition to boosting weight loss and helping knee pain.

• In a ​Phase 3 trial, Lilly found a weekly injection of retatrutide reduced moderate-to-severe obstructive sleep apnea severity by 60.6% in adults with obesity. Lilly's older drug Zepbound is approved for the condition.

• ‌In the same ⁠trial, the drug reduced knee osteoarthritis pain by up to 73.1%, Lilly found. The results were ⁠presented at an American Diabetes Association conference in New Orleans.

• Lilly previously disclosed results of the two studies presented on ​Saturday showing ​patients with obesity lost ​28% of body weight and ‌adults with type 2 diabetes experienced significant drops in blood sugar levels.

• In one of the studies, 2% of patients with diabetes who took the lowest dose of the drug experienced major adverse cardiovascular events. Such events were not ‌necessarily caused by the drug, ​according to detailed results published in ​the Lancet on Saturday.

• ​Retatrutide is Lilly's experimental "triple G" drug, which ‌targets GLP-1, a second obesity-related hormone ​called GIP ​and the body's receptors for a third hormone called glucagon.

• The Indiana-based company and rivals including Denmark's Novo ​Nordisk are in ‌a race to dominate the booming market for obesity ​and diabetes drugs.

(Reporting by Chris Prentice; Editing by ​Caroline Humer and Will Dunham)